Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Crovalimab - Chugai Pharmaceutical/Roche

Next Previous
Drug Profile

Crovalimab - Chugai Pharmaceutical/Roche

Alternative Names: Anti-C5 recycling antibody - Chugai Pharmaceutical/Roche; CH-7092230; Crovalimab-akkz; Piasky; RG 6107; RO 7092230; RO-7112689; RO-711269; RO7112689/F01; SKY-59

Latest Information Update: 28 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Roche
  • Class Antianaemics; Monoclonal antibodies; Urologics
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Paroxysmal nocturnal haemoglobinuria
  • Phase III Atypical Haemolytic Uraemic Syndrome
  • Discontinued Lupus nephritis; Sickle cell anaemia

Most Recent Events

  • 28 Oct 2025 No recent reports of development identified for phase-I development in Sickle-cell-anaemia(In adolescents, In adults) in Kenya (IV, Infusion)
  • 28 Oct 2025 No recent reports of development identified for phase-I development in Sickle-cell-anaemia(In adolescents, In adults) in Lebanon (IV, Infusion)
  • 23 Oct 2025 Discontinued - Phase-I for Sickle cell anaemia (In adults, In adolescents) in Kenya,Lebanon (IV) (Roche pipeline, October 2025) (Chugai Pharmaceutical pipeline, October 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top